Peptide research often focuses on signaling systems that regulate metabolism, tissue repair, inflammation, or cellular communication. PT-141, commonly known as bremelanotide, stands apart because much of its scientific history centers on the brain.
PT-141 is a synthetic melanocortin peptide analog studied for its interaction with melanocortin receptors, particularly neural receptor systems associated with motivation, behavioral signaling, and sexual response. Early research identified activity at melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R), receptor subtypes strongly represented within the central nervous system. [1,2]
That makes PT-141 an interesting example of how peptide signaling can connect molecular receptor activity with complex neurobiological behavior.
What Is PT-141?
PT-141 is a synthetic cyclic peptide derived from the melanocortin family of signaling molecules and is commonly identified scientifically as bremelanotide.
Its development grew from research involving α-melanocyte-stimulating hormone (α-MSH) and synthetic melanocortin analogs. PT-141 emerged from work on melanotan II and related molecules as researchers investigated how structural changes to melanocortin peptides influenced receptor activity and physiological responses. [1,3]
Unlike research strategies aimed primarily at peripheral vascular tissue, PT-141 became notable for evidence suggesting a centrally mediated mechanism involving neuronal melanocortin pathways. [1,4]
The Melanocortin System
The melanocortin system consists of peptide signaling molecules and five known melanocortin receptor subtypes: MC1R through MC5R. MC3R and MC4R are particularly interesting because they are strongly associated with neural signaling and substantial expression within the central nervous system. [2]
Research involving melanocortin signaling has extended into energy homeostasis and feeding behavior, autonomic regulation, motivation and reward circuitry, hypothalamic signaling, and reproductive and sexual behavior.
Why MC4R Is Especially Interesting
Among PT-141's receptor interactions, MC4R has received considerable attention. Experimental studies using genetic, anatomical, and pharmacological approaches have demonstrated that MC4R participates in neuronal pathways associated with sexual behavior and erectile physiology. [5]
This helped establish an important research concept: sexual-response signaling is not exclusively a vascular phenomenon. Neural circuits can influence the initiation, motivation, and coordination of physiological responses.
PT-141 and the Hypothalamus
One particularly important region in this research is the hypothalamus. Early PT-141 experiments reported neuronal activation within hypothalamic regions following systemic administration in animal models. [1]
Subsequent preclinical bremelanotide research focused more specifically on areas such as the medial preoptic area (mPOA). In female animal models, researchers investigated appetitive sexual behavior, neural activation within hypothalamic and limbic regions, and interactions between melanocortin signaling and dopamine. [6]
Melanocortins and Dopamine Signaling
Melanocortin receptors do not operate in isolation. Neurobiological research suggests that melanocortin pathways interact with broader neurotransmitter systems involved in motivation and behavioral response.
One proposed mechanism involves MC4R signaling within the medial preoptic area influencing dopaminergic activity. Dopamine is an important neurotransmitter in motivation, reward, and sexual-response circuitry. [6,7]
This does not mean PT-141 can be reduced to a simple “dopamine peptide.” Instead, it illustrates how peptide receptor systems can modulate larger neural networks rather than acting through a single isolated pathway.
Research in Both Male and Female Models
Melanocortin signaling has been investigated in both male and female sexual-response models. Early preclinical studies examined erectile responses and hypothalamic activation in male animals, while subsequent work explored motivation and appetitive sexual behavior in female models. [1,6] Human clinical research later investigated bremelanotide in both male and female populations. [4,8]
The literature helped broaden scientific understanding of sexual response from a purely peripheral model toward one incorporating central neural signaling, motivation, receptor biology, and behavioral circuitry.
From Research Peptide to Clinically Studied Molecule
PT-141 is also noteworthy because its research history eventually extended beyond laboratory models. Bremelanotide underwent clinical investigation and ultimately became an FDA-approved pharmaceutical for a specific indication in premenopausal women. Reviews published after approval summarize its development and clinical research. [9,10]
However, pharmaceutical bremelanotide and laboratory research materials should not be treated as interchangeable. Azyven Research products are supplied strictly for laboratory research and analytical use and are not pharmaceutical products intended for human or veterinary use.
Technical Identity
PT-141 is commonly characterized in the scientific literature as a synthetic cyclic melanocortin peptide and α-MSH analog with agonist activity at melanocortin receptors, including MC3R and MC4R. [1,2] The name bremelanotide is widely used in the published scientific and pharmaceutical literature for PT-141.
Specific identity, purity, molecular characteristics, and analytical results for an individual research material should always be evaluated using the applicable lot-specific analytical documentation or Certificate of Analysis (COA) rather than inferred solely from the commonly recognized identity of PT-141.
Why Researchers Study PT-141
PT-141 occupies an unusual position within peptide science because it connects several areas of research that are often studied separately: peptide chemistry → melanocortin receptor pharmacology → hypothalamic signaling → neurotransmitter interactions → motivation and behavioral physiology.
That progression makes PT-141 useful for understanding a broader principle of peptide biology: a relatively small signaling molecule can interact with a receptor system that ultimately participates in large-scale neural and behavioral networks.
Explore PT-141 at Azyven Research
Azyven Research offers PT-141 10 mg for qualified laboratory research and analytical applications.
Explore PT-141 at Azyven Research →
Azyven Research materials are sold strictly for research and analytical purposes only. Not for human or veterinary use.
References & Further Reading
1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96–102. DOI: 10.1111/j.1749-6632.2003.tb03167.x. PMID: 12851303.
2. Ericson MD, et al. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules. 2022;12(10):1407. DOI: 10.3390/biom12101407. PMID: 36291616.
3. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006. PMID: 16412534.
4. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137–1144. DOI: 10.2174/156802607780906681. PMID: 17584134.
5. Van der Ploeg LHT, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA. 2002. PMID: 12172010.
6. Pfaus JG, et al. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007. PMID: 17958619.
7. Clayton AH, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022. PMID: 33455598.
8. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628–638. DOI: 10.1111/j.1743-6109.2006.00268.x. PMID: 16839319.
9. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599–1606. DOI: 10.1007/s40265-019-01187-w. PMID: 31429064.
10. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020;54(7):684–690. DOI: 10.1177/1060028019899152. PMID: 31893927.